Zacks Research Upgrades AC Immune (NASDAQ:ACIU) to Hold

AC Immune (NASDAQ:ACIU) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other research firms have also issued reports on ACIU. Wall Street Zen raised AC Immune from a “hold” rating to a “buy” rating in a research report on Tuesday, May 13th. BTIG Research restated a “buy” rating and set a $8.00 target price on shares of AC Immune in a research note on Monday. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, AC Immune currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

AC Immune Stock Performance

Shares of ACIU opened at $2.40 on Tuesday. The company’s 50-day simple moving average is $2.16 and its 200-day simple moving average is $1.98. AC Immune has a 1 year low of $1.43 and a 1 year high of $3.98. The stock has a market capitalization of $240.98 million, a PE ratio of -4.14 and a beta of 1.61.

AC Immune (NASDAQ:ACIU) last released its earnings results on Tuesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). The business had revenue of $1.65 million for the quarter, compared to analyst estimates of $1.98 million. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%. On average, sell-side analysts predict that AC Immune will post -0.62 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Sei Investments Co. acquired a new stake in shares of AC Immune during the 2nd quarter worth about $51,000. Acadian Asset Management LLC increased its stake in AC Immune by 87.1% in the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after purchasing an additional 172,796 shares during the last quarter. BVF Inc. IL raised its holdings in AC Immune by 1.5% during the first quarter. BVF Inc. IL now owns 19,822,436 shares of the company’s stock worth $37,068,000 after purchasing an additional 300,000 shares in the last quarter. Banque Cantonale Vaudoise purchased a new stake in shares of AC Immune during the 1st quarter worth approximately $50,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of AC Immune during the 4th quarter worth approximately $118,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.